公开(公告)号：US20210040127A1

公开(公告)日：2021-02-11

申请号：US16977253

申请日：2019-03-08

Applicant: Merck Sharp & Dohme Corp.

Inventor： Abdelghani Abe Achab ,  Matthew L. Childers ,  Jared N. Cumming ,  Christian A. Fischer ,  Symon Gathiaka ,  Hakan Gunaydin ,  Charles A. Lesburg ,  Derun Li ,  Min Lu ,  Anandan Palani ,  Rachel L. Palte ,  Qinglin Pu ,  David L. Sloman ,  Sung-Sau So ,  Chunrui Sun ,  Hongjun Zhang

IPC: C07F5/02 ,  C07K16/28

Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.

公开(公告)号：US20190269679A1

公开(公告)日：2019-09-05

申请号：US16462344

申请日：2017-12-11

Applicant: Merck Sharp & Dohme Corp.

Inventor： John S. Debenham ,  Jason M. Cox ,  Ping Lan ,  Zhongxiang Sun ,  Zhe Feng ,  Chunrui Sun ,  Michael W. Seganish ,  Zhong Lai ,  Cheng Zhu ,  Thomas Bara ,  Murali Rajagopalan ,  Qun Dang ,  Hyunjin M. Kim ,  Bin Hu ,  Jinglai Hao

IPC: A61K31/497 ,  A61K31/4439 ,  A61K31/42 ,  A61K31/444 ,  C07D417/14 ,  C07D413/04 ,  C07D413/14 ,  C07D231/20

Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.